Categories AlphaGraphs, Earnings, Health Care
Infographic: Highlights of Abiomed (ABMD) Q4 2020 earnings report
Medical device maker Abiomed, Inc. (NASDAQ: ABMD) reported a decline in fourth quarter earnings even as revenues remained flat. The company withheld its full-year guidance, citing the uncertainties caused by the Covid-19 outbreak. Following the announcement, the stock gained sharply in early trading on Thursday.
Net income dropped 57% annually to $31.8 million or $0.70 per share and came in below analysts’ estimates. At $206.7 million, revenue was unchanged year-over-year.
In the US, revenues of Impella dropped 3%, while revenues of the flagship product rose 12% in the international market. Abiomed’s stock dropped 31% in the past twelve months. After slipping to a multi-year low last month, the stock is regaining strength.
Most Popular
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company
Walgreens Boots Alliance set to report earnings next week. Here’s what to expect
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the drug store chain that is expanding into a diversified healthcare provider, is on a restructuring drive aimed at better aligning the business with